390 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Manufacturers with published third-party certificates of analysis for Liraglutide. Open a vendor to see every batch we've verified.
This methodology study, once completed, is important because it will provide specific, quantified data on how **liraglutide** impacts food intake in obese individuals. Understanding the precise mechanisms and magnitud…
A pragmatic clinical study will compare **semaglutide** (Wegovy) to four other anti-obesity medications for weight loss, physical function, and quality of life in US employees.
A 14-week, randomized Phase 3 trial evaluates **Liraglutide**'s effect on blood glucose in **Type 2 Diabetes** subjects.
**Liraglutide's efficacy in prediabetes appears highly dependent on sex and reproductive status**, suggesting a need for personalized treatment approaches. This research highlights that women, particularly those of fe…
This research expands the therapeutic potential of **Liraglutide** beyond metabolic disorders, suggesting a novel application in inflammatory bone diseases. For peptide users and clinicians, this indicates that GLP-1R…
This research highlights a promising synergistic strategy for combating **Type 2 diabetes**-associated sarcopenia, a condition where muscle loss exacerbates metabolic dysfunction. **Combining HMB with Liraglutide coul…
This study underscores that **liraglutide's efficacy in obese adolescents may be less pronounced than in adults**, suggesting that current GLP-1 protocols might require significant optimization for younger populations…
This review establishes a **biologically plausible hypothesis** for GLP-1RAs in periodontal health, extending their known anti-inflammatory benefits beyond metabolic disease. While current evidence is exclusively prec…
This research provides critical insights into the dynamic mechanisms of **liraglutide**, suggesting that its primary mode of action shifts with the progression of metabolic disease. **This understanding could lead to …
Understanding the nature of **Liraglutide**-induced pancreatic enzyme elevations is critical for patient reassurance and clinical practice. If this study confirms that these elevations are due to adaptive, non-inflamm…
Understanding the real-world utilization of **liraglutide** for weight management is critical for clinicians, policymakers, and patients. While clinical trials establish efficacy and safety under controlled conditions…
A 26-week trial compared a generic liraglutide injection against brand-name Victoza® for glycemic control, safety, and immunogenicity in type 2 diabetes patients.
A multinational trial investigated the efficacy and safety of switching from **sitagliptin** to **liraglutide** in **Type 2 Diabetes** patients inadequately controlled on sitagliptin and metformin.
This substudy will investigate ultrasound changes in obese knee osteoarthritis patients after an 8-week diet-induced weight loss intervention.
Liraglutide is being studied to assess its safety and efficacy in reducing opioid craving and preventing early relapse in patients with opioid use disorder.
This study highlights that **liraglutide offers distinct and superior renoprotective benefits over dapagliflozin in mitigating inflammation and fibrosis in diabetic kidney disease**, even when dapagliflozin is co-admi…
GLP-1 receptor agonism represents a promising, novel therapeutic strategy for **PTSD** and related anxiety disorders, extending beyond its established metabolic benefits. **This research suggests that GLP-1 agonists l…
Regular physical activity emerges as a critical component for promoting **vascular health** and reducing **inflammation** in adults with obesity, even when using GLP-1R agonists for weight maintenance. This finding su…
This research highlights a potential novel application for **liraglutide** beyond its established metabolic roles, suggesting it could serve as a prophylactic agent against gastric mucosal damage. For individuals at h…
A post-marketing surveillance study in Asia is evaluating the real-world safety and effectiveness of **liraglutide** (Victoza®) in type 2 diabetes patients on non-sulfonylurea antidiabetic agents.
This case report highlights a potentially significant shift in the management paradigm for **HNF4A MODY**. Traditionally, `sulfonylureas` are the go-to, but **oral semaglutide** offers a novel, non-sulfonylurea option…
**MK-8521** represents a potential new therapeutic agent for **Type 2 Diabetes** patients whose glycemic control is insufficient with metformin alone. If this preliminary study and subsequent trials demonstrate favora…
A clinical trial aimed to assess if **liraglutide** plus canagliflozin could prevent compensatory hepatic glucose production (HGP) and enhance glycemic control, weight loss, and blood pressure in Type 2 Diabetes.
Liraglutide's potential drug-drug interactions with atorvastatin, lisinopril, griseofulvin, and digoxin, and its influence on intragastric pH, are being investigated.
This observational study is crucial for refining **Type 2 Diabetes** management by providing real-world insights into **ASCVD** risk stratification and the targeted use of **Glucagon-like peptide-1 receptor agonists**…
This study clarifies the specific role of **Type IIB PKA** as a critical mediator for `GLP-1R` agonists like **liraglutide** in enhancing insulin secretion. For peptide users and clinicians, this research highlights t…
This meta-analysis suggests that **adjunctive GLP-1 RA therapy can provide a short-term boost to weight loss outcomes after bariatric surgery**, particularly within the first 6 months. For individuals experiencing sub…
This study aims to clarify how **liraglutide** and **insulin detemir** interact to influence **myocardial glucose uptake** in T2D patients. If synergy is demonstrated, it could lead to **optimized combination therapie…
XW003, a novel GLP-1 analogue, was evaluated against liraglutide for body weight reduction in obese adults, demonstrating its efficacy.
If **Liraglutide** proves superior or offers a viable alternative to existing treatments like colesevelam for **bile acid malabsorption**, it could significantly **expand therapeutic options for patients suffering fro…
A Phase 1 trial aims to evaluate liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in obese children aged 7-11.
Liraglutide will be tested for its effects on cognitive function in HIV-infected, overweight/obese T2DM patients.
The FIGHT trial investigates if subcutaneous GLP-1 agonist therapy improves clinical stability at six months in patients discharged after **Acute Heart Failure Syndrome**.
This study, once its results are published, will provide crucial evidence for clinicians and patients struggling with **Type 2 Diabetes** management. If **IDegLira** demonstrates superior or non-inferior glycemic cont…
If this trial demonstrates positive results, **liraglutide could become a crucial pharmacological tool for treating adolescent obesity**, offering a much-needed option beyond lifestyle interventions alone. Currently, …
This review underscores that **GLP-1 receptor agonists offer a critical strategy to manage severe metabolic complications** in patients on essential antipsychotics, potentially improving long-term health outcomes and …
While specific results from this trial are not available in the provided abstract, the investigation of **Liraglutide** in a triple combination with rosiglitazone and metformin highlights a strategy for intensifying *…
The comparative effectiveness of **insulin glargine** versus **liraglutide** in T2D patients who have failed oral agents is a critical clinical question. If one agent demonstrates clear superiority in achieving glycem…
**Establishing the optimal sequence and combination of therapies for Type 2 Diabetes is critical for improving patient outcomes.** If this trial's full results demonstrate superior or non-inferior glycemic control wit…
If successful, this study could establish **MEDI0382 as a promising therapeutic candidate for T2DM**, particularly for patients struggling with associated hepatic complications like NAFLD. By targeting hepatic glycoge…
Understanding **Liraglutide's** impact on left ventricular function in **chronic heart failure (CHF)** patients, particularly those with co-existing **Type 2 Diabetes**, could significantly inform future treatment str…
This study provides compelling preclinical evidence that **liraglutide could be a novel therapeutic strategy for nicotine addiction**, potentially offering a new avenue for smoking cessation. By targeting the **orexin…
This case underscores that **liraglutide, despite its general safety, can rarely cause severe idiosyncratic hepatocellular injury**. For clinicians and patients using `GLP-1 RA`s, vigilance for unexplained elevations …
If **Liraglutide** were shown to effectively reduce dietary lipid-induced **insulin resistance**, it would significantly broaden its therapeutic utility beyond current glycemic control. This could lead to **improved m…
If CinnaGen-liraglutide demonstrates non-inferiority to Victoza®, it could significantly impact the **treatment landscape for Type II diabetes**. The introduction of a biosimilar or bioequivalent liraglutide could lea…
If this trial demonstrates positive outcomes, **Liraglutide could become a valuable adjunctive therapy for overweight Type 1 Diabetes patients on insulin pumps**, potentially improving glycemic control and reducing in…
If successful, this trial could establish **insulin degludec/liraglutide** as a superior treatment option for Chinese **Type 2 Diabetes Mellitus** patients whose `HbA1c` levels are not adequately managed by OADs alone…
A Phase 1 trial assessed the safety, tolerability, and pharmacokinetics of **Liraglutide-depot** in healthy subjects in the USA.
Liraglutide is hypothesized to improve glycemic control in uncontrolled type 1 diabetic patients, with an expected **1% reduction** in `HbA1c` from baseline.
Free, no account — handy when you're working with Liraglutide.